Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Gilles, Defer"'
Autor:
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1385-1401 (2024)
Abstract Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient
Externí odkaz:
https://doaj.org/article/b321bac547dd4d7899d298075a610cb1
Autor:
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1457-1476 (2023)
Abstract Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart
Externí odkaz:
https://doaj.org/article/b62d819588be411fa00cad4f58746437
Autor:
Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer
Publikováno v:
Neurology and Therapy, Vol 12, Iss 2, Pp 529-542 (2023)
Abstract Introduction Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended i
Externí odkaz:
https://doaj.org/article/7ab6cfd0c28d47328cdce3b6dc0d39a9
Autor:
Jerome De Sèze, Laurent Suchet, Claude Mekies, Eric Manchon, Pierre Labauge, Anne-Marie Guennoc, Gilles Defer, Pierre Clavelou, Giovanni Castelnovo, Bertrand Bourre, Caroline Bensa-Koscher, Abdullatif Al Khedr, Julie Le Mao, Lauriane Villemur, Stephane Bouée, Laura Luciani, Patrick Vermersch
Publikováno v:
Neurology and Therapy, Vol 12, Iss 2, Pp 351-369 (2022)
Abstract The treatment strategy in relapsing multiple sclerosis (RMS) is a complex decision requiring individualization of treatment sequences to maximize clinical outcomes. Current local and international guidelines do not provide specific recommend
Externí odkaz:
https://doaj.org/article/d85d74469802470f8b09b57b68dc090b
Autor:
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer
Publikováno v:
Neurology and Therapy, Vol 13, Iss 1, Pp 255-256 (2023)
Externí odkaz:
https://doaj.org/article/e3d9e2e289314c2f9330874b941881d8
Autor:
Sarah Wilson, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Laure Tron, Sandra Vukusic, Emmanuelle Le Page, Marc Debouverie, Jonathan Ciron, Aurélie Ruet, Jérôme De Sèze, Hélène Zephir, Thibault Moreau, Christine Lebrun-Frénay, David-Axel Laplaud, Pierre Clavelou, Pierre Labauge, Eric Berger, Jean Pelletier, Olivier Heinzlef, Eric Thouvenot, Jean Philippe Camdessanché, Emmanuelle Leray, Olivier Dejardin, Gilles Defer
Publikováno v:
The Lancet Regional Health. Europe, Vol 24, Iss , Pp 100542- (2023)
Summary: Background: The effects of socio-economic status on mortality in patients with multiple sclerosis is not well known. The objective was to examine mortality due to multiple sclerosis according to socio-economic status. Methods: A retrospectiv
Externí odkaz:
https://doaj.org/article/ed163a351a914b918dd49d51d455ef33
Autor:
Caroline Harand, France Daniel, Audrey Mondou, Damien Chevanne, Christian Creveuil, Gilles Defer
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Cognitive and mood disorders negatively impact daily life in patients with multiple sclerosis (MS). Pharmacological treatments did not demonstrate any effect on cognition compared with cognitive rehabilitation (CR). However, if CR
Externí odkaz:
https://doaj.org/article/40be0338d7d4437795abd564cae17d5e
Autor:
Kathy Khoy, Delphine Mariotte, Gilles Defer, Gautier Petit, Olivier Toutirais, Brigitte Le Mauff
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS) with an autoimmune component. Among the recent disease-modifying treatments available, Natalizumab, a monoclonal antibody directed against the alpha chain of th
Externí odkaz:
https://doaj.org/article/c0aac8f89e9a4cc3ab493d319c2acd41
Autor:
Bruno Brochet, Pierre Clavelou, Gilles Defer, Jérôme De Seze, Céline Louapre, Eloi Magnin, Aurélie Ruet, Catherine Thomas-Anterion, Patrick Vermersch
Publikováno v:
Brain Sciences, Vol 12, Iss 2, p 183 (2022)
Background: Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype. Aims: This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). I
Externí odkaz:
https://doaj.org/article/2d31837f18ee4d378e9091b8a5c4a5bc
Autor:
Gilles Defer, Florian Le Caignec, Sophie Fedrizzi, François Montastruc, Damien Chevanne, Jean-Jacques Parienti, Laure Peyro-Saint-Paul
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS patients in Fra
Externí odkaz:
https://doaj.org/article/77c7b46c0d0046f09d8f680b823e5a45